Artivion, a medical device company that manufactures implantable tissues for cardiac and vascular transplant applications, says its services have been “disrupted” due to a cybersecurity incident.
Artivion, Inc. engages in the research and development of solutions which address cardiac and vascular surgeons' clinical challenges in treating patients with aortic diseases. Its products include ...
Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Artivion AORT in the last three months. The following table encapsulates their recent ...
In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on Artivion (AORT – Research Report), with a price target of $35.00. The company’s shares closed last Friday ...
Needham analyst Michael Matson has reiterated their bullish stance on AORT stock, giving a Buy rating yesterday. Michael Matson’s rating is based on several favorable developments for Artivion.